CA3142494A1 - Sustained-release compositions of alpha-ketoglutarate - Google Patents

Sustained-release compositions of alpha-ketoglutarate Download PDF

Info

Publication number
CA3142494A1
CA3142494A1 CA3142494A CA3142494A CA3142494A1 CA 3142494 A1 CA3142494 A1 CA 3142494A1 CA 3142494 A CA3142494 A CA 3142494A CA 3142494 A CA3142494 A CA 3142494A CA 3142494 A1 CA3142494 A1 CA 3142494A1
Authority
CA
Canada
Prior art keywords
composition
ketoglutarate
release
calcium
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3142494A
Other languages
English (en)
French (fr)
Inventor
David Eugene Pereira
Sumana Konar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ponce De Leon Health Designated Activity Co
Original Assignee
Ponce De Leon Health Designated Activity Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ponce De Leon Health Designated Activity Co filed Critical Ponce De Leon Health Designated Activity Co
Publication of CA3142494A1 publication Critical patent/CA3142494A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CA3142494A 2019-06-10 2020-06-10 Sustained-release compositions of alpha-ketoglutarate Pending CA3142494A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962859595P 2019-06-10 2019-06-10
US62/859,595 2019-06-10
US201962929024P 2019-10-31 2019-10-31
US62/929,024 2019-10-31
PCT/US2020/036987 WO2020252014A1 (en) 2019-06-10 2020-06-10 Sustained-release compositions of alpha-ketoglutarate

Publications (1)

Publication Number Publication Date
CA3142494A1 true CA3142494A1 (en) 2020-12-17

Family

ID=73781275

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3142494A Pending CA3142494A1 (en) 2019-06-10 2020-06-10 Sustained-release compositions of alpha-ketoglutarate

Country Status (11)

Country Link
US (1) US20220265586A1 (enExample)
EP (1) EP3980001B1 (enExample)
JP (2) JP7751291B2 (enExample)
KR (1) KR20220044478A (enExample)
CN (1) CN114126601B (enExample)
BR (1) BR112021024952A2 (enExample)
CA (1) CA3142494A1 (enExample)
DK (1) DK3980001T3 (enExample)
IL (1) IL288782A (enExample)
TW (1) TWI869410B (enExample)
WO (1) WO2020252014A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7499259B2 (ja) * 2018-09-25 2024-06-13 ポンス デ レオン ヘルス デジグネイテッド アクティビティ カンパニー αケトグルタル酸カルシウムを製造するためのプロセス
MX2024008182A (es) * 2021-12-29 2024-09-24 Jrs Pharma Gmbh & Co Kg Lubricante para productos farmacéuticos y nutracéuticos.
WO2024123738A1 (en) * 2022-12-06 2024-06-13 Ponce De Leon Health Designated Activity Company Compositions and methods for treating diseases responsive to akg-vitamin b coadministration

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US6905707B2 (en) * 1998-05-28 2005-06-14 Medical Research Institute Controlled release arginine alpha ketoglutarate
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
CO5140079A1 (es) * 1998-10-14 2002-03-22 Novartis Ag Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
CN100400042C (zh) 1999-12-03 2008-07-09 聚合化学股份公司 制备生物利用度改善的麦角生物碱持续释放药物组合物的方法及其组合物
JP4169596B2 (ja) * 2000-12-20 2008-10-22 アルコン、インコーポレイテッド 白内障を液化破壊により取り除くための溶液
US20060029668A1 (en) 2002-10-24 2006-02-09 Ron Eyal S Sustained release L-arginine formulations and methods of manufacture and use
CA2574597A1 (en) * 2004-08-09 2006-02-16 Cancer Research Technology Limited Alpha-ketoglutarates and their use as therapeutic agents
FR2967578B1 (fr) 2010-11-18 2012-12-28 Advicenne Pharma Composition pharmaceutique comportant des sels de citrate et de bicarbonate, et son utilisation pour le traitement de la cystinurie
ITBO20120226A1 (it) * 2012-04-24 2013-10-25 Alfa Wassermann Spa Composizioni comprendenti ornitina alfa-chetoglutarato, processi per il loro ottenimento e il loro uso.
MX377119B (es) * 2013-06-06 2025-03-07 Amip Llc Un sistema de dosis no alimenticia suministrable oralmente que comprende hierro y un agente.
ITFI20130184A1 (it) 2013-08-01 2015-02-02 Valpharma Internat S P A Una formulazione farmaceutica di gliclazide a rilascio modificato, somministrabile per via orale, e suo metodo di produzione.
CN108653221B (zh) * 2015-06-03 2021-09-07 南京三迭纪医药科技有限公司 药品剂型及其使用
EP3518915A4 (en) * 2016-09-30 2020-04-15 The Regents of the University of California ALPHA KETOBUTYRATE, ALPHA KETOGLUTARATE AND 2-HYDROXYBUTYRATE FOR STIMULATING HAIR GROWTH
KR20180062063A (ko) * 2016-11-30 2018-06-08 (주) 메티메디제약 서방형 항암용 약학 조성물
MX2017004010A (es) * 2017-03-27 2018-02-09 Antonio Hernandez Miramontes Jorge Mezcla de oxalacetato, alfacetoglutarato, ácido tartánico y sales de lactato de calcio y sodio, para tratar pacientes con insuficiencia renal crónica.
KR102643567B1 (ko) 2017-04-25 2024-03-05 버크 인스티튜트 포 리서치 온 에이징 수명 및 건강수명을 연장시키기 위한 제제

Also Published As

Publication number Publication date
EP3980001B1 (en) 2025-08-27
CN114126601B (zh) 2025-07-15
CN114126601A (zh) 2022-03-01
JP2025124683A (ja) 2025-08-26
WO2020252014A1 (en) 2020-12-17
TWI869410B (zh) 2025-01-11
KR20220044478A (ko) 2022-04-08
EP3980001A4 (en) 2023-06-21
JP2022537685A (ja) 2022-08-29
US20220265586A1 (en) 2022-08-25
EP3980001A1 (en) 2022-04-13
TW202112362A (zh) 2021-04-01
JP7751291B2 (ja) 2025-10-08
BR112021024952A2 (pt) 2022-02-15
IL288782A (en) 2022-02-01
DK3980001T3 (da) 2025-12-01
AU2020292278A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
US20220168255A1 (en) Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose
US20190254978A1 (en) Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
JP2025124683A (ja) アルファ－ケトグルタル酸塩の持続放出組成物
US20110223249A1 (en) Extended release compositions comprising mycophenolate sodium and processes thereof
US12178918B2 (en) Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US20150030676A1 (en) Stablized modified release folic acid derivative composition, its therapeutic use and methods of manufacture
EP1849830B1 (en) Finely divided composition containing poorly water soluble substance
AU2020292278B2 (en) Sustained-release compositions of alpha-ketoglutarate
TWI414322B (zh) Preparation of lozenges
US20080199527A1 (en) Enteric Coated Azithromycin Multiparticulates
HK40071632A (en) Sustained-release compositions of alpha-ketoglutarate
JPH08208517A (ja) 成形物およびその製造方法
JP2000103746A (ja) 成形物およびその製造方法
EP2543363A1 (en) Sustained release pharmaceutical oral solid dosage forms of dronedarone or one of its pharmaceutically acceptable salts
US20240024246A1 (en) Stable prolonged release formulation of vitamin c and a process for preparation thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211201

EEER Examination request

Effective date: 20211201

EEER Examination request

Effective date: 20211201

EEER Examination request

Effective date: 20211201

EEER Examination request

Effective date: 20211201

EEER Examination request

Effective date: 20211201

EEER Examination request

Effective date: 20211201

EEER Examination request

Effective date: 20211201